Corcept Therapeutics swings to loss as ALS drug misses Phase 2 primary endpoint
Updated
Updated · MarketWatch · Apr 30
Corcept Therapeutics swings to loss as ALS drug misses Phase 2 primary endpoint
11 articles · Updated · MarketWatch · Apr 30
The company posted a $31.8 million first-quarter loss on revenue of $164.9 million, versus a $20.3 million profit a year earlier and below FactSet revenue expectations.
Corcept said dazucorilant failed to show a functional difference versus placebo, but patients on a higher dose for two years showed an 87% lower risk of death on the secondary endpoint.
It raised full-year revenue guidance to $950 million-$1.05 billion, above analyst forecasts, and said it is working with regulators to start a pivotal Phase 3 study later this year.
Can a surprising survival benefit turn a failed ALS drug trial into a groundbreaking medical success?
If a new drug extends life for ALS patients without improving function, is it truly a victory?